FDMT (4D Molecular Therapeutics) Institutional Ownership: 103.32% (As of Jul. 07, 2026)


FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $12.82
GF Value $215.68
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Institutional Ownership?

4D Molecular Therapeutics FDMT +0.83% 55 Institutional Ownership is 103.32% as of Jul. 07, 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $215.68 (Possible Value Trap). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 4D Molecular Therapeutics's institutional ownership is 103.32%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 4D Molecular Therapeutics's Insider Ownership is 3.75%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 4D Molecular Therapeutics's Float Percentage Of Total Shares Outstanding is 86.49%.

4D Molecular Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Institutional Ownership Chart

4D Molecular Therapeutics Historical Data

The historical data trend for 4D Molecular Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 36.05 35.82 32.78 36.88 37.24 38.12 36.19 36.86 40.12 41.22
FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 103.32% mean?
4D Molecular Therapeutics (FDMT) has a Institutional Ownership of 103.32% as of Jul. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on 4D Molecular Therapeutics and its competitors.
Is 4D Molecular Therapeutics' Institutional Ownership too high?
4D Molecular Therapeutics' current Institutional Ownership is 103.32%. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Institutional Ownership compare to TECX and ACHV?
4D Molecular Therapeutics' Institutional Ownership of 103.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Institutional Ownership is 103.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $215.68, compared to a current price of $12.82 — trading 94.1% below its estimated fair value. The current Institutional Ownership is 103.32%. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Institutional Ownership is 103.32% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $12.82 is trading 94.1% below its estimated GF Value™ of $215.68. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Institutional Ownership: 103.32%
  • GF Value™: $215.68 vs. price of $12.82 (94.1% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.82
Price
$215.68
GF Value